Site selection is one of the most consequential decisions in the execution of a clinical trial. A strong site delivers clean data, meets enrollment targets, and maintains protocol compliance throughout the study lifecycle. A weak site – regardless of how capable it appeared during feasibility – can delay a study, compromise data integrity, or force a sponsor to reallocate enrollment mid-protocol.

The challenge for pharmaceutical sponsors and CROs is that site selection is often conducted under time pressure, with limited on-site visibility, and based on information the site itself has provided. The sites that look best on paper are not always the sites that perform best in practice.

This article offers a practical framework for evaluating clinical trial sites in the Chicago area – the criteria that matter, the questions to ask, and the signals that distinguish a site worth partnering with from one that carries risk.

Why Site Selection Determines Study Outcomes

Over 80 percent of clinical trials miss their original enrollment timelines. The most common reason is not a flawed protocol or an unpromising therapeutic candidate. It is underperforming sites – sites that were selected based on optimistic feasibility projections rather than demonstrated operational capability.

The downstream consequences are significant. Enrollment delays extend timelines and increase costs. Protocol deviations compromise data quality and regulatory submissions. Sites that cannot deliver what they projected damage the sponsor relationship in ways that are difficult to recover. A rigorous site evaluation process is not due diligence for its own sake – it is the most direct investment a sponsor can make in the success of the study.

Six Criteria That Separate High-Performing Sites From Risky Ones

1 Regulatory and Inspection History
The FDA's inspection history for a site is one of the most objective data points available to a sponsor evaluating a research site. Sites with a history of Form 483 observations, warning letters, or voluntary action indicated findings carry regulatory risk that affects not just their own data - it can affect the credibility of an entire submission if data from that site is included.
What to ask: Has the site been inspected by the FDA? What were the findings? How were they resolved? Is the site currently inspection-ready - and what does that mean in their specific operational context?
Inspection-ready is a phrase that appears frequently in site profiles. But there is a significant difference between a site that claims inspection-readiness and one that maintains the documentation discipline, delegation logs, source record quality, and protocol compliance systems that FDA inspectors actually evaluate. Ask for specifics, not assurances.
ARC maintains inspection-ready operations as an operational standard - not a periodic state. Our documentation practices, delegation logs, and source record quality are maintained to FDA audit standards continuously, regardless of whether an inspection is scheduled.
2 Enrollment Performance and Participant Pipeline
Enrollment projections submitted during feasibility are the single most commonly overstated metric in clinical trial site selection. A site that projects 15 participants per month but consistently delivers 4 creates a cascading problem - amended timelines, renegotiated milestones, and often a sponsor covering the cost of recruiting an alternative site mid-study.
The most reliable indicator of future enrollment performance is past enrollment performance. Ask for enrollment data from the site's previous studies in the same therapeutic area - not projections, not capacity estimates, but actual delivery against committed targets.
What distinguishes a genuinely high-enrollment site from one that can only project high numbers is the participant pipeline infrastructure. A site that recruits every study from zero - through physician referrals and community outreach that begin only after a protocol is signed - will always be slower than a site that maintains an ongoing digital recruitment system with a warm database of pre-interested participants.
ARC operates a structured participant recruitment program using digital lead generation - a pipeline of pre-interested adults in the Chicago metro area who have expressed interest in clinical research before any specific study protocol is open. When a new study activates, enrollment does not begin from zero. It begins from a warm, pre-screened population.
Step 3 Investigator Qualifications and Clinical Leadership
The principal investigator is ultimately responsible for the conduct of the trial at site level. Their clinical qualifications, their therapeutic area expertise, and their direct involvement in day-to-day study operations are all material factors in site selection.
A site where the PI is a nationally recognised expert who is rarely present and has delegated all trial responsibilities to a coordinator team presents different risks than a site with a clinician-led team where the PI is directly involved in participant assessments, protocol decisions, and data oversight.
What to verify: Current medical licensure. GCP certification and when it was last renewed. Protocol-specific training records. Whether the PI has direct patient contact in the therapeutic area of the study. The delegation of authority structure - who is authorised to perform what procedures and on what basis.
At ARC, our principal investigators are active clinicians with direct patient care experience in the therapeutic areas we research. Investigator-led oversight is built into every study - protocol questions do not escalate through a coordinator to an unavailable PI. They are resolved by a physician who is present and informed.
4 Source Documentation and Data Quality Standards
Data quality begins at source documentation. The accuracy, completeness, and contemporaneity of source records is what makes the data from a site usable in a regulatory submission. Sites that reconstruct records, rely on informal note-taking, or have weak source-to-CRF reconciliation processes create data that requires extensive query resolution and carries the risk of regulatory scrutiny.
During a feasibility visit or site initiation, review source document examples - redacted as necessary for privacy - to assess the quality and consistency of record-keeping. Ask about the site's deviation management process: how deviations are identified, documented, root-caused, and reported. A site that discovers deviations during monitoring visits rather than before them has a reactive compliance posture. A site that identifies, documents, and reports its own deviations before a monitor arrives is managing compliance proactively.
This distinction matters significantly during an FDA inspection. Inspectors evaluate not just whether deviations occurred - they occur at every site - but whether the site's systems caught them, responded appropriately, and implemented corrective actions. A proactive deviation management system is a signal of genuine operational maturity.
5 Protocol Compliance Track Record
Protocol deviations are inevitable in clinical research. What separates high-performing sites from problematic ones is not a zero deviation rate - it is the type, frequency, and management of deviations that occur.
Eligibility violations - enrolling participants who do not meet inclusion/exclusion criteria - are among the most serious deviation categories. They produce data that cannot be used and participants who may not have been appropriately protected. A site with a history of eligibility violations at any frequency warrants careful scrutiny.
Procedural deviations - missed timepoints, out-of-window visits, incomplete assessments - are more common and generally less consequential, but a high volume signals a site that is overextended or poorly organised. Ask for the site's protocol deviation log from a comparable recent study. The volume, pattern, and quality of responses will tell you more about a site's operational capability than any feasibility questionnaire.
6 Staffing Stability and Operational Continuity
Study coordinator turnover is one of the most disruptive and underappreciated risk factors in clinical site evaluation. A coordinator who leaves mid-study takes institutional knowledge, participant relationships, and operational continuity with them. Sites with high staff turnover - common in the competitive Chicago healthcare labour market - require more sponsor oversight, generate more queries, and are more likely to experience protocol deviations during transition periods.
Ask about the tenure of the site's current study coordinator team. Ask whether the coordinator who will be assigned to your study has previous experience in the therapeutic area. Ask what the site's protocol is for study continuity if a coordinator leaves mid-study.
Staffing stability is not just a people issue - it is a data quality issue. The relationship between a consistent, experienced coordinator and a study's participants directly affects screening rates, retention, and the quality of data collected at each visit.

The Chicago Market – What to Know

Chicago offers genuine advantages for clinical trial site selection. A large, diverse urban population provides access to patient demographics that increasingly matter to sponsors – particularly for studies where FDA guidance emphasises diversity in enrollment. The city’s academic medical centres and hospital systems mean a higher-than-average concentration of patients actively managed for chronic conditions across multiple therapeutic areas.

For sponsors selecting sites in the Chicago market specifically, the West Side and broader metropolitan area offer access to populations with significant unmet medical need and strong interest in clinical research participation when that research is presented accessibly and respectfully. ARC’s location at 5351 W. North Ave places us at the centre of this population.

The Chicago clinical research landscape also includes several sites that carry legacy reputations built on academic affiliations rather than operational performance. Academic affiliation and operational excellence are not the same thing. A site’s historical relationship with a medical school tells you about its research culture. It does not tell you about its current source documentation practices, coordinator stability, or enrollment delivery against committed targets.

What a Strong Site Looks Like at ARC

American Research Center was built around the operational standards that sponsors need most: inspection-ready documentation maintained continuously, a clinician-led investigator team with direct patient care experience, a structured digital participant pipeline that removes the enrollment-from-zero problem, and a coordinator team with genuine therapeutic area experience.

We are a Phase II and Phase III site with experience across Oncology, CNS, and Infectious Diseases. Our site has been inspection-ready in its operations since inception – not as a periodic exercise before FDA visits, but as the standard to which our team works every day.

If you are evaluating clinical research sites in Chicago for an upcoming study, we welcome a site visit, a feasibility conversation, or a review of our capability documentation. Our team is available to answer the specific questions this article raises – and to provide the data, not just the assurances, that rigorous site selection requires.

Making Contact

Sponsor and CRO enquiries are welcomed directly through our website at theamericanresearch.com, via our For Sponsors & CROs page, or by contacting our team at our facility at 5351 W. North Ave, Chicago, IL 60639.

We respond to sponsor enquiries within one business day and are available for site visits, capability presentations, or feasibility calls at short notice. If you are assembling a site list for an upcoming protocol, we are ready to provide the information you need to make an informed evaluation.